Lung cancer study halted: Drug-Radiation combo fails to show promise
NCT ID NCT04786093
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study aimed to see if combining the immunotherapy drug durvalumab with precise, high-dose radiation could improve quality of life for people with advanced non-small cell lung cancer. It planned to enroll many participants but was stopped early after only one person joined. The approach used two different radiation schedules, but the study did not gather enough data to draw conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.